Search results
Results from the WOW.Com Content Network
3-Methylmethcathinone (3-MMC), also known as metaphedrone, [4] is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity.
Systematic reviews and meta-analyses of clinical research using low doses of certain central nervous system stimulants found that these drugs may enhance cognition in healthy people. [ 13 ] [ 14 ] [ 15 ] In particular, the classes of stimulants that demonstrate possible cognition-enhancing effects in humans have evidence in vitro as direct ...
Research chemicals are chemical substances scientists use for medical and scientific research purposes. One characteristic of a research chemical is that it is for ...
The letters were issued earlier this month to Synthetix, which sells drugs on a website called Helix Chemical Supply, and US Chem Labs after the U.S. regulator conducted a review of their ...
Cayman Chemical Company is an American biotechnology company founded in 1980, headquartered in Ann Arbor, Michigan. [1] The company provides chemicals that are used primarily by universities and pharmaceutical companies for research and the development of medicines .
4-Methoxyphencyclidine (methoxydine, 4-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. [1]
Chemical Society Reviews publishes "Tutorial reviews" and "Critical reviews". The former are written to be of relevance both to the general research chemist who is new to the field, as well as the expert, whereas the latter aim to provide a deeper understanding of the topic in hand, but retain their accessibility through an introduction written for the general reader.
Pyrazolam (SH-I-04) [2] is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s. [3] It has since been "rediscovered" and sold as a designer drug since 2012.